XNAS · LXEO
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$4.69

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is LXEO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Lexeo Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2023
Employees
59
Country
US

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.69
Last session
Day high
$4.69
Last session
Day low
$4.69
Last session
Previous close
$4.69
52W high
$5.04
-6.94% from high
52W low
$4.13
62% of range
Market cap
$368.3M
EPS
$-2.1700
Shares out
78.5M
VWAP
$4.69
Last session
Price history computed in-house
1W
-1.26%
SMA 50 $4.73 · below
SMA 200 $4.73 · below
52W position 62%
Veridion warehouse edge

Warehouse intelligence for LXEO.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

LXEO insider activity

Lexeo Therapeutics, Inc. Common Stock

Score
Coverage building
Pressure
Net selling
Filings
28
Buys / sells
3 / 25
Net value
-$678K
Insiders
5
Named filers
TN
Townsend Richard Nolan
Insider
Leadership
OM
Otero Jose Manuel
Insider
Leadership
SS
See Tai Sandi
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$678K across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-04-072026-04-06Townsend Richard NolanInsidersell$5.6955,000340,106$313KSEC Form 4
2026-03-172026-03-13Otero Jose ManuelInsiderbuy$2.645,930131,390$16KSEC Form 4
2026-03-172026-03-13Townsend Richard NolanInsiderbuy$2.642,623395,106$7KSEC Form 4
2026-02-202026-02-18Otero Jose ManuelInsidersell$6.403,016125,460$19KSEC Form 4
2026-02-202026-02-18Townsend Richard NolanInsidersell$6.3810,173392,483$65KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 23 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

LXEO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LXEO in this window.
Lobbying spend

LXEO lobbying filings, year to date.

Registered lobbying filings matched to Lexeo Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LXEO in this window.
Latest news · LXEO
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for LXEO.
Options
Sovereign unlock shows live options positioning for LXEO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.